- Previous Close
0.2010 - Open
0.1905 - Bid 0.1910 x --
- Ask 0.1980 x --
- Day's Range
0.1900 - 0.1970 - 52 Week Range
0.1510 - 0.4280 - Volume
69,148 - Avg. Volume
107,907 - Market Cap (intraday)
66.505M - Beta (5Y Monthly) 1.91
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.74
Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under Preclinical development stage. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. Spago Nanomedical AB (publ) was incorporated in 1999 and is based in Lund, Sweden.
spagonanomedical.seRecent News: SPAGO.ST
View MorePerformance Overview: SPAGO.ST
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SPAGO.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SPAGO.ST
View MoreValuation Measures
Market Cap
66.51M
Enterprise Value
34.04M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
34.93
Price/Book (mrq)
--
Enterprise Value/Revenue
17.81
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-45.53%
Return on Equity (ttm)
-87.21%
Revenue (ttm)
6.91M
Net Income Avi to Common (ttm)
-32.51M
Diluted EPS (ttm)
-0.1100
Balance Sheet and Cash Flow
Total Cash (mrq)
32.47M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-25.8M